Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.

IF 0.7 Q4 RESPIRATORY SYSTEM Lung Cancer Management Pub Date : 2020-03-04 DOI:10.2217/lmt-2019-0011

Dolores Isla, Bartomeu Massuti, Martín Lázaro, Lucía Ruiz de Alda, Rocio Gordo, Nuria Ortega-Joaquín, Itziar Oyagüez

{"title":"Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.","authors":"Dolores Isla, Bartomeu Massuti, Martín Lázaro, Lucía Ruiz de Alda, Rocio Gordo, Nuria Ortega-Joaquín, Itziar Oyagüez","doi":"10.2217/lmt-2019-0011","DOIUrl":null,"url":null,"abstract":"Aim: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib.Methods: Management cost/year (€ 2018) in patients with and without BM was estimated with disaggregated resource consumption provided by local oncologists, including medical visits, hospitalizations, diagnostic/laboratory tests, imaging techniques and surgical procedures. The comparison of costs/year with alectinib and crizotinib, considered the cumulative 12-month incidence of BM in ALEX trial (9.4 and 41.4%, respectively).Results: Management cost was €6173.42/patient-year without BM and €21,637.50/patient-year with BM. With alectinib, average cost/patient was lower than crizotinib (€4948.51/patient-year).Conclusion: Prevention of BM with alectinib may result in reductions of cost/year in the management of advanced ALK+ NSCLC.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 1","pages":"LMT28"},"PeriodicalIF":0.7000,"publicationDate":"2020-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0011","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2019-0011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib.

Methods: Management cost/year (€ 2018) in patients with and without BM was estimated with disaggregated resource consumption provided by local oncologists, including medical visits, hospitalizations, diagnostic/laboratory tests, imaging techniques and surgical procedures. The comparison of costs/year with alectinib and crizotinib, considered the cumulative 12-month incidence of BM in ALEX trial (9.4 and 41.4%, respectively).

Results: Management cost was €6173.42/patient-year without BM and €21,637.50/patient-year with BM. With alectinib, average cost/patient was lower than crizotinib (€4948.51/patient-year).

Conclusion: Prevention of BM with alectinib may result in reductions of cost/year in the management of advanced ALK+ NSCLC.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

晚期ALK+ NSCLC患者脑转移治疗的成本分析:阿勒替尼与克唑替尼

目的:评估伴有和不伴有脑转移(BM)的NSCLC ALK+患者的管理成本，并比较阿勒替尼或克唑替尼治疗患者的年成本。方法:根据当地肿瘤学家提供的分类资源消耗，包括就诊、住院、诊断/实验室检查、成像技术和外科手术，估计有和没有BM的患者的管理成本/年(€2018)。与阿勒替尼和克唑替尼的成本/年比较，考虑了ALEX试验中累积12个月的BM发病率(分别为9.4%和41.4%)。结果:无BM的管理成本为6173.42欧元/患者-年，有BM的管理成本为21637.50欧元/患者-年。使用阿勒替尼，每位患者的平均成本低于克唑替尼(4948.51欧元/患者年)。结论:阿勒替尼预防脑转移可降低晚期ALK+ NSCLC治疗的年成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lung Cancer Management RESPIRATORY SYSTEM-

CiteScore

2.30

自引率

0.00%

发文量